Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Trial Details

NCT ID
NCT06057402
Phase
PHASE4
Sponsor
Pfizer
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Elranatamab
Locations (sample)
  • Irvine, California, United States|33.66946,-117.82311
  • Orange, California, United States|33.78779,-117.85311
  • Orange, California, United States|33.78779,-117.85311
  • Fort Collins, Colorado, United States|40.58526,-105.08442
  • Fort Collins, Colorado, United States|40.58526,-105.08442

Key Eligibility Criteria

  • Participants must agree to follow the reproductive criteria as outlined in the protocol
  • Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deri…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →